| dc.contributor |
Médecins Sans Frontières-Holland (MSF-H) Kala-azar Programme, South Sudan/Kenya. |
|
| dc.creator |
Moore, E |
|
| dc.creator |
O'Flaherty, D |
|
| dc.creator |
Heuvelmans, H |
|
| dc.creator |
Seaman, J |
|
| dc.creator |
Veeken, H |
|
| dc.creator |
de Wit, S |
|
| dc.creator |
Davidson, R N |
|
| dc.date |
2001 |
|
| dc.date.accessioned |
2017-01-31T07:09:16Z |
|
| dc.date.available |
2017-01-31T07:09:16Z |
|
| dc.identifier |
Comparison of Generic and Proprietary Sodium Stibogluconate for the Treatment of Visceral Leishmaniasis in Kenya. 2001, 79 (5):388-93 Bull. World Health Organ. |
|
| dc.identifier |
0042-9686 |
|
| dc.identifier |
11417033 |
|
| dc.identifier |
http://hdl.handle.net/10144/17263 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/17263 |
|
| dc.identifier |
Bulletin of the World Health Organization |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/17263 |
|
| dc.description |
OBJECTIVE: To compare the use of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis (kala-azar). METHODS: A total of 102 patients with confirmed kala-azar were treated in a mission hospital in West Pokot region, Kenya, with sodium stibogluconate (20 mg/kg/day for 30 days)--either as Pentostam (PSM) or generic sodium stibogluconate (SSG); 51 patients were allocated alternately to each treatment group. FINDINGS: There were no significant differences in baseline demographic characteristics or disease severity, or in events during treatment. There were 3 deaths in the PSM group and 1 in the SSG group; 2 patients defaulted in each group. Only 1 out of 80 test-of-cure splenic aspirates was positive for Leishmania spp.; this patient was in the SSG group. Follow-up after > or = 6 months showed that 6 out of 58 patients had relapsed, 5 in the SSG group and 1 in the PSM group. No outcome variable was significantly different between the two groups. CONCLUSION: The availability of cheaper generic sodium stibogluconate, subject to rigid quality controls, now makes it possible for the health authorities in kala-azar endemic areas to provide treatment to many more patients in Africa. |
|
| dc.language |
en |
|
| dc.publisher |
Published by WHO |
|
| dc.relation |
http://www.who.int/bulletin/en |
|
| dc.rights |
Archived on this site with permission of WHO |
|
| dc.title |
Comparison of Generic and Proprietary Sodium Stibogluconate for the Treatment of Visceral Leishmaniasis in Kenya. |
|